Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
PORTAL HYPERTENSION: MODERN DIAGNOSIS AND TREATMENT
Tojiddinov Kh.S.
Andijan State Medical Institute , Republic of Uzbekistan, Andijan
Abstract:
Portal hypertension is a common and serious complication of chronic liver
disease, particularly cirrhosis. It is defined by an increase in the pressure within the portal
venous system and is responsible for significant morbidity and mortality due to
complications such as variceal bleeding, ascites, and hepatic encephalopathy. With
advancements in diagnostic imaging and therapeutic interventions, the management of portal
hypertension has significantly improved in recent years. This article explores the
pathophysiology, current diagnostic modalities, and state-of-the-art treatment options for
portal hypertension, highlighting recent innovations and clinical strategies.
Key words:
portal hypertension, treatment, diagnosis, blood vassels.
Introduction: Portal hypertension (PH) is characterized by elevated blood pressure in the
portal vein, typically resulting from resistance to blood flow through the liver. This
condition most frequently arises due to cirrhosis, in which normal liver tissue is replaced
with fibrotic tissue that disrupts normal vascular architecture. Clinically significant portal
hypertension is defined as a hepatic venous pressure gradient (HVPG) of 10 mmHg or more.
It is a key driver of life-threatening complications in liver disease, and timely intervention is
essential for patient survival.
Pathophysiology of Portal Hypertension: Portal hypertension develops due to a combination
of increased vascular resistance within the liver and increased splanchnic blood flow. In
cirrhosis, the architecture of the liver is distorted by fibrosis and regenerative nodules, which
increase intrahepatic vascular resistance. At the same time, vasodilators such as nitric oxide
lead to dilation of splanchnic arteries, increasing blood flow into the portal system and
compounding the hypertension.
Collateral blood vessels may form to divert blood from the high-pressure portal system to
the systemic circulation. These vessels are often fragile and located in areas such as the
esophagus and stomach, where they form varices that are prone to rupture and bleeding.
Portal hypertension is a condition defined by an abnormal elevation of blood pressure within
the portal venous system, typically when the hepatic venous pressure gradient (HVPG)
exceeds 5 mmHg. Clinically significant portal hypertension (CSPH) is defined at ≥10–12
mmHg and is commonly seen in chronic liver diseases, particularly cirrhosis.
Understanding the pathophysiology involves identifying the site of increased resistance, the
mechanisms involved, and systemic changes that result from sustained portal pressure
elevation. Portal Venous System Overview: The portal venous system drains blood from the
gastrointestinal tract, spleen, pancreas, and gallbladder into the liver. The portal vein is
formed by the confluence of the superior mesenteric vein and the splenic vein. Normally, the
portal pressure ranges between 5–10 mmHg. When this pressure increases beyond normal,
portal hypertension develops.
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
These factors make blood flow through the liver more difficult, raising pressure upstream in
the portal vein.
Increased Portal Blood Inflow
Due to splanchnic arterial vasodilation in response to portal hypertension and liver
dysfunction.
Mediated by nitric oxide (NO), carbon monoxide, glucagon, and vascular endothelial
growth factor (VEGF).
This vasodilation causes hyperdynamic circulation — high cardiac output, low
systemic vascular resistance.
Increased blood volume delivered to the portal vein exacerbates the already elevated
pressure.Clinical Manifestations: The clinical manifestations of portal hypertension depend
on its severity and underlying cause. Common features include:
Splenomegaly: Enlargement of the spleen due to congestion.
Ascites: Accumulation of fluid in the peritoneal cavity.
Esophageal and gastric varices: Fragile veins prone to bleeding.
Caput medusae: Dilated periumbilical veins visible on the abdominal wall.
Hepatic encephalopathy: Cognitive dysfunction due to the accumulation of toxins
not cleared by the liver.
Thrombocytopenia and anemia: Resulting from splenic sequestration and blood loss.
Non-Invasive Diagnostics
Ultrasound with Doppler is typically the first-line diagnostic tool. It allows for visualization
of portal vein flow, measurement of portal vein diameter, and detection of thrombosis.
Transient elastography (FibroScan) is widely used to assess liver stiffness, indirectly
reflecting portal pressure.
CT and MRI provide more detailed imaging of the liver and vasculature. They are
particularly useful in identifying collateral vessels and evaluating the presence of
hepatocellular carcinoma. Endoscopic Evaluation: Esophagogastroduodenoscopy (EGD)
remains the gold standard for the detection of varices. It allows direct visualization and
classification of varices, enabling appropriate prophylactic or therapeutic interventions.
Invasive Measurement:Hepatic venous pressure gradient (HVPG) measurement is the most
accurate method for diagnosing portal hypertension. It involves catheterization of the hepatic
vein and provides quantitative data on the severity of the condition. An HVPG ≥10 mmHg is
associated with the development of complications such as varices.
Treatment Strategies: Medical Management: The first line of treatment often involves non-
selective beta-blockers (NSBBs) such as propranolol, nadolol, or carvedilol. These
medications reduce cardiac output and splanchnic vasodilation, thereby decreasing portal
pressure.Diuretics, particularly spironolactone and furosemide, are used to manage ascites.
Albumin infusions are indicated in patients undergoing large-volume paracentesis or
experiencing hepatorenal syndrome.For acute variceal bleeding, vasoactive agents such as
octreotide or terlipressin are administered to reduce splanchnic blood flow.Endoscopic
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Interventions:Endoscopic variceal ligation (EVL) is the preferred method for controlling
active esophageal variceal bleeding and preventing recurrence. It is more effective and safer
than sclerotherapy, which is now used mainly when ligation is not possible. Interventional
Radiology:In patients with recurrent variceal bleeding or refractory ascites, a transjugular
intrahepatic portosystemic shunt (TIPS) is often indicated. This procedure involves placing a
stent between the portal and hepatic veins, creating a low-resistance pathway for blood flow
and reducing portal pressure.
Though effective, TIPS is associated with an increased risk of hepatic encephalopathy and
requires careful patient selection.Surgical Approaches: Surgical shunts are rarely performed
today due to the invasiveness and potential complications. However, they may be considered
in patients who are not candidates for TIPS and have preserved liver function. Liver
Transplantation:Liver transplantation remains the definitive treatment for patients with end-
stage liver disease and portal hypertension. It not only cures the underlying liver pathology
but also reverses portal hypertension and its complications.
Emerging Therapies and Research: Recent research has explored the use of statins for
reducing intrahepatic resistance and improving endothelial function. Additionally,
antifibrotic agents are being developed to target liver fibrosis directly.The role of the gut-
liver axis is increasingly recognized, and interventions aimed at modifying the intestinal
microbiome, such as rifaximin and probiotics, show promise in reducing systemic
inflammation and hepatic encephalopathy.Advanced biomarkers, imaging techniques, and
AI-assisted diagnostics are also improving the ability to detect portal hypertension and
predict complications before they arise.
Prognosis and Monitoring: Patients with portal hypertension require lifelong monitoring,
even when asymptomatic. Regular surveillance for varices (via endoscopy), hepatocellular
carcinoma (via imaging and alpha-fetoprotein levels), and evaluation of liver function are
essential for managing the condition and improving outcomes.
Conclusion:
Portal hypertension is a complex and progressive condition primarily resulting
from chronic liver diseases like cirrhosis. With modern diagnostic tools and therapeutic
strategies, including pharmacological agents, endoscopic techniques, and radiological
interventions, the management of portal hypertension has greatly evolved. Liver
transplantation remains the ultimate cure, but early diagnosis and multidisciplinary care can
significantly prolong survival and enhance quality of life. Ongoing research into novel
therapies holds promise for even better outcomes in the future.
Literature:
1.
Bosch, J., Garcia-Pagan, J. C. (2010). "Complications of Cirrhosis: Portal
Hypertension."
Gastroenterology
.
2.
Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A., Bosch, J. (2017). "Portal
Hypertension and Variceal Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and
Management."
Hepatology
.
3.
Tripathi, D., Stanley, A. J., Hayes, P. C., et al. (2015). "UK Guidelines on the
Management of Variceal Haemorrhage in Cirrhotic Patients."
Gut
.
Vo
lu
m
e
5,
M
ay
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
4.
Sobirjonovich, S. I. (2023). Systemic Organization of Professional Competence,
Creativity and Innovative Activity of A Future Kindergartener.
Journal of Pedagogical
Inventions and Practices
,
19
, 108-112.
5.
Мухамедова, М. Г., Куртиева, Ш. А., & Назарова, Ж. А. (2020). СИНДРОМ
ФУНКЦИОНАЛЬНОЙ КАРДИОПАТИИ У СОВРЕМЕННЫХ ПОДРОСТКОВ. In
П84
Профилактическая медицина-2020: сборник научных трудов Все-российской научно-
практической конференции с международным участи-ем. 18–19 ноября 2020 года/под
ред. АВ Мельцера, ИШ Якубовой. Ч. 2.—СПб.: Изд-во СЗГМУ им. ИИ Мечникова,
2020.—304 с.
(p. 105).
6.
Юллиев, Н. Ж. (2022). Определение физической подготовленности спасателей
в условиях среднегорья. In
ТРУДЫ ХIII ЕВРАЗИЙСКОГО НАУЧНОГО ФОРУМА
(pp.
259-262).
7.
Файзуллаев, Т., & Хужамбердиева, Ш. (2020). ЭРКИН ВОҲИДОВ ИЖОДИНИ
УМУМИЙ ЎРТА ТАЪЛИМ МАКТАБЛАРИДА ЎРГАНИШДА ЁШЛАРНИ
ВАТАПАРВАРЛИК РУҲИДА ТАРБИЯЛАШНИНГ АҲАМИЯТИ.
Scientific Bulletin of
Namangan State University
,
2
(4), 543-546.
8.
Boymirzayeva, S. (2025). DIDACTIC FORMS AND METHODS OF
PEDAGOGICAL SUPPORT AND TARGETED DEVELOPMENT OF CHILDREN IN
THE PROCESS OF PRESCHOOL EDUCATION.
Journal of Multidisciplinary Sciences
and Innovations
,
1
(1), 557-562.
9.
Mukhamedova, M., & Arnopolskaya, D. (2013). The Nitric Oxide System in Patients
with Chronic Heart Failure.
International Journal of Biomedicine
,
3
(3), 180-183.
10.
Юллиев, Н. Ж., Сафарова, Д. Д., Мусаева, У. А., & Нурбаев, Б. Ш. (2015).
Особенности физической подготовки спасателей МЧС с учетом условий
среднегорья.
Наука и спорт: современные тенденции
,
8
(3), 47-53.
11.
Khujamberdieva, S. (2023). SPECIFIC TASKS OF INTRODUCING CHILDREN
TO LITERARY WORKS.
Collection of scientific papers «SCIENTIA»
, (May 5, 2023;
Sydney, Australia), 145-147.
12.
European Association for the Study of the Liver (EASL). (2018). "EASL Clinical
Practice Guidelines: Management of Portal Hypertension."
Journal of Hepatology
.
